Erythropoietin - Protein Sciences

Drug Profile

Erythropoietin - Protein Sciences

Alternative Names: rEPO - Protein Sciences

Latest Information Update: 12 Nov 2010

Price : $50

At a glance

  • Originator Protein Sciences Corporation
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 31 Mar 2008 This programme is still in active development
  • 12 Sep 2005 Profile reviewed with information available at the BIO-2005 conference
  • 14 Jul 2004 This compound is available for licensing (http://www.proteinsciences.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top